



November 12, 2022

**The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001**

Dear Sir,

Subject: Submission of outcome of Board Meeting in compliance with the Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

With reference to above mentioned Subject, we hereby inform you that Board of Directors of the Company at their Meeting held today i.e. on Saturday, November 12, 2022 and they have inter alia approved:

1. Unaudited Standalone & Consolidated Financial Results as per the Indian Accounting Standards (Ind AS) along with the Limited Review report issued by Statutory Auditor for the quarter and half year ended on September 30, 2022;

The meeting commenced at 11.00 a.m. and concluded at 11.45 a.m.

Please find attached herewith, the approved Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for the quarter and half year ended on September 30, 2022

You are requested to take the note of the same.

Thanking you

**Yours Sincerely
For TRANSGENE BIOTEK LIMITED**

**DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR
DIN: 02287235**

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 2022

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Audited)	30.09.2022 (UnAudited)	30-09-2021 (Audited)	31.03.2022 (Audited)
1	Revenue from operations	-	5,50,847	16,949	5,50,847	16,949	8,66,949
2	Other income (net)	4,38,470	4,38,470	4,38,470	8,76,940	8,76,940	21,25,324
3	Total income (1 + 2)	4,38,470	9,89,317	4,55,419	14,27,787	8,93,889	29,92,273
4	EXPENSES						
	Cost of materials consumed	4,894	7,204	31,639	12,098	92,558	(4,62,132)
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	7,45,857	7,46,157	6,54,777	14,92,014	13,10,598	28,78,842
	Finance costs	4,53,410	4,53,410	5,66,950	9,06,819	11,33,900	22,67,800
	Depreciation and amortisation expense	123,77,921	123,74,307	247,05,193	247,52,228	494,10,385	992,43,559
	Other expenses	45,51,962	12,90,740	5,24,922	58,42,702	10,86,871	30,84,248
	Total expenses	181,34,044	148,71,818	264,83,481	330,05,861	530,34,312	1070,12,317
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(176,95,574)	(138,82,501)	(260,28,062)	(315,78,074)	(521,40,423)	(1040,20,044)
6	Exceptional item (net)	-	-	-	-	-	-
7	Profit before tax (5 - 6)	(176,95,574)	(138,82,501)	(260,28,062)	(315,78,074)	(521,40,423)	(1040,20,044)
8	Tax expense						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
9	Profit for the year (7 - 8)	(176,95,574)	(138,82,501)	(260,28,062)	(315,78,074)	(521,40,423)	(1040,20,044)
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(176,95,574)	(138,82,501)	(260,28,062)	(315,78,074)	(521,40,423)	(1040,20,044)
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.23)	(0.18)	(0.34)	(0.42)	(0.69)	(1.37)
	Diluted (Rs.)	(0.23)	(0.18)	(0.34)	(0.42)	(0.69)	(1.37)

Notes:

1. We are waiting to receive the Regulatory approvals to conduct pre-clinical studies on Nasal Insulin (Nozulín).
2. During the quarter, the company received an order from the SEBI Adjudication Officer dated 30/08/2022 imposing a penalty of Rs.38 lacs in connection with the GDR issue. The management has filed an appeal at SAT on this and waiting for the hearing to take place.
3. With the emergence of additional and important evidences strengthening our earlier made claims, we submitted those to the relevant agencies within and outside India for recovery and restoration of lost GDR funds.
4. No. of investor complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0. taken on record by the Board of Directors of the Company at their meeting held on 12th November 2022.

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director

Date:12.11.2022
Place:Hyderabad


TRANSGENE BIOTECH LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

Standalone Statement of assets and liabilities as on September 30, 2022

PARTICULARS	As at 30 September 2022	As at 31 March 2022
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	180,22,288	184,67,547
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	712,10,875	955,03,182
(g) Intangible assets under development	186,76,633	186,76,633
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	10,50,140	10,50,140
(ii) Trade Receivables	-	-
(iii) Loans	2302,04,250	2302,04,250
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	14,55,134	13,97,088
SUB-TOTAL	3406,19,320	3652,98,840
CURRENT ASSETS		
(a) Inventories	9,46,220	9,46,220
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Cash and cash equivalents	68,546	56,849
(iv) Bank Balances other than (iii) above	30,234	94,378
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	58,51,258	58,03,058
SUB-TOTAL	68,96,258	69,00,505
Non-Current Assets Classified as Held for Sale		-
TOTAL ASSETS	3475,15,578	3721,99,345

EQUITY AND LIABILITIES	As at 30 September 2022	As at 31 March 2022
EQUITY		
Equity share capital	7577,00,000	7577,00,000
Other equity	-7912,48,280	-7596,70,206
SUB-TOTAL	-335,48,280	-19,70,206
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	-	-
(i) Borrowings	485,96,787	476,89,968
(ii) Trade Payable	-	-
(iii) Other financial liabilities	-	-

(b) Provisions	2302,04,250	2302,04,250
(c) Deferred tax liabilities (net)	-	-
(d) Other non-current liabilities	43,84,703	52,61,643
SUB-TOTAL	2831,85,740	2831,55,861
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	769,09,582	724,66,000
(ii) Trade payables	13,23,401	20,27,760
(iii) Other financial liabilities	-	-
(b) Provisions	179,39,561	141,47,676
(c) Other current liabilities	17,05,573	23,72,254
(d) Current tax liabilities (net)	-	-
SUB-TOTAL	978,78,117	910,13,690
TOTAL EQUITY AND LIABILITIES	3475,15,578	3721,99,345
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

Contingent Liabilities:

1. The appeal filed against the Income tax demand for FY 2011-12 (AY 2012-13) has been accepted and demand has been nullified by the department with order dated 24/08/2021. The provision has been created through Retained earnings in previous years hence reversed it through the same. However, the income tax department has filed appeal to high court against this order. Hence the demand amount of Rs.5.96 Crores is treated as contingent liability.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 12.11.2022

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, Sangareddy Dist.

Standalone Unaudited Statement of Cash Flows for the half year ended September 30, 2022

Particulars	For the period ended September 2022		For the period ended September 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(315,78,074)		(521,40,423)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	247,52,228		494,10,385	
Finance costs	9,06,819		11,33,900	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(67,95,967)	-	(24,73,078)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables			-	
Other non-current assets			-	
Other Current assets	(48,200)		94,790	
Inventories	-			
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(7,04,359)		(3,72,863)	
Provision (CL)	37,91,885		5,400	
Borrowing (CL)	44,43,582		16,50,001	
Other financial liabilities				
Other current liabilities	(6,66,681)		11,08,973	
Provison (NCL)			-	
Cash generated from operations		20,260		13,223
Net income tax paid		-		-
Net cash flow from operating activities (A)		20,260		13,223
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	(14,661)			
Investments	-			
Non Current Assets	(58,046)		(59,887)	
Net cash (used in) / flow from investing activities (B)		(72,707)		(59,887)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		(52,447)		(46,664)
Cash and cash equivalents at the beginning of the year		1,51,227		1,41,743
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year		98,780		95,079

For and on behalf of the Board of Directors

M/s TRANSGENE BIOTEK LIMITED



Dr.K K Koteswara Rao
Chairman & Managing Director
DIN:02287235
Place: Hyderabad
Date: 12.11.2022



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 2022

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Audited)	30.09.2022 (UnAudited)	30-09-2021 (Audited)	31.03.2022 (Audited)
1	Revenue from operations	-	5,50,847	16,949	5,50,847	16,949	8,66,949
2	Other income (net)	4,38,470	4,38,470	4,38,470	8,76,940	8,76,940	21,25,324
3	Total income (1 + 2)	4,38,470	9,89,317	4,55,419	14,27,787	8,93,889	29,92,273
4	EXPENSES						
	Cost of materials consumed	4,894	7,204	31,639	12,098	92,558	(4,62,132)
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	7,45,857	7,46,157	6,54,777	14,92,014	13,10,598	28,78,842
	Finance costs	4,53,410	4,53,410	5,66,950	9,06,819	11,33,900	22,67,800
	Depreciation and amortisation expense	123,77,921	123,74,307	247,05,193	247,52,228	494,10,385	992,43,559
	Other expenses	45,51,960	12,90,740	5,30,133	58,42,700	10,92,082	30,92,858
	Total expenses	181,34,042	148,71,818	264,88,692	330,05,859	530,39,523	1070,20,928
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(176,95,572)	(138,82,501)	(260,33,273)	(315,78,072)	(521,45,634)	(1040,28,655)
6	Exceptional item (net)	-	-	-	-	-	-
7	Profit before tax (5 - 6)	(176,95,572)	(138,82,501)	(260,33,273)	(315,78,072)	(521,45,634)	(1040,28,655)
8	Tax expense						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	Total tax expense	-	-	-	-	-	-
9	Profit for the year (7 - 8)	(176,95,572)	(138,82,501)	(260,33,273)	(315,78,072)	(521,45,634)	(1040,28,655)
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(176,95,572)	(138,82,501)	(260,33,273)	(315,78,072)	(521,45,634)	(1040,28,655)
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)						
	Basic (Rs.)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Diluted (Rs.)	(0.23)	(0.18)	(0.34)	(0.42)	(0.69)	(1.37)
		(0.23)	(0.18)	(0.34)	(0.42)	(0.69)	(1.37)

Notes:

1. We are waiting to receive the Regulatory approvals to conduct pre-clinical studies on Nasal Insulin (Nozulin).
2. During the quarter, the company received an order from the SEBI Adjudication Officer dated 30/08/2022 imposing a penalty of Rs.38 lacs in connection with the GDR issue. The management has filed an appeal at SAT on this and waiting for the hearing to take
3. With the emergence of additional and important evidences strengthening our earlier made claims, we submitted those to the relevant agencies within and outside India for recovery and restoration of lost GDR funds.
4. No. of investor complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
5. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date:12.11.2022
Place:Hyderabad




TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollarum, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

Consolidated Statement of assets and liabilities as on September 30, 2022

PARTICULARS	As at 30 September 2022	As at 31 March 2022
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	180,22,288	184,67,547
(b) Right of Use Assets	-	-
(c) Capital work-in-progress	-	-
(d) Investment Properties	-	-
(e) Goodwill	-	-
(f) Other intangible assets	712,10,875	955,03,182
(g) Intangible assets under development	186,76,633	186,76,633
(h) Biological Assets Other Than Bearer Plants	-	-
(i) Financial assets	-	-
(i) Investments	9,50,150	9,50,150
(ii) Trade Receivables	-	-
(iii) Loans	13290,24,004	13290,24,004
(iv) Other Financial Assets	-	-
(j) Deferred Tax Assets (Net)	-	-
(k) Other non-current assets	14,55,134	13,97,088
SUB-TOTAL	14393,39,084	14640,18,604
CURRENT ASSETS		
(a) Inventories	9,46,220	9,46,220
(b) Financial assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	84,460.00	84,460.00
(iii) Cash and cash equivalents	68,546	56,849
(iv) Bank Balances other than (iii) above	30,234	94,378
(v) Loans	-	-
(vi) Other Financial Assets	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	58,51,258	58,03,058
SUB-TOTAL	69,80,718	69,84,965
Non-Current Assets Classified as Held for Sale		-
TOTAL ASSETS	14463,19,802	14710,03,569

EQUITY AND LIABILITIES	As at 30 September 2022	As at 31 March 2022
EQUITY		
Equity share capital	7577,00,010	7577,00,010
Other equity	-6155,04,084	-5839,26,012
SUB-TOTAL	1421,95,926	1737,73,998
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	-	-

(i) Borrowings	485,96,787	476,89,968
(ii) Trade Payable	-	-
(iii) Other financial liabilities	-	-
(b) Provisions	11522,13,978	11522,13,978
(c) Deferred tax liabilities (net)	-	-
(d) Other non-current liabilities	43,84,703	52,61,643
SUB-TOTAL	12051,95,468	12051,65,589
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	768,33,563	723,89,981
(ii) Trade payables	13,23,401	20,27,760
(iii) Other financial liabilities	11,26,311	11,26,311
(b) Provisions	179,39,561	141,47,676
(c) Other current liabilities	17,05,573	23,72,254
(d) Current tax liabilities (net)	-	-
SUB-TOTAL	989,28,409	920,63,982
TOTAL EQUITY AND LIABILITIES	14463,19,804	14710,03,569
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

Contingent Liabilities:

1. The appeal filed against the Income tax demand for FY 2011-12 (AY 2012-13) has been accepted and demand has been nullified by the department with order dated 24/08/2021. The provision has been created through Retained earnings in previous years hence reversed it through the same. However, the income tax department has filed appeal to high court against this order. Hence the demand amount of Rs.5.96 Crores is treated as contingent liability.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao

Managing Director



Date: 12.11.2022

Place:Hyderabad



TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, Sangareddy Dist

Consolidated Unaudited Statement of Cash Flows for the half year ended September 30, 2022

Particulars	For the period ended September 2022		For the period ended September 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(315,78,072)		(521,40,423)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	247,52,228		494,10,385	
Finance costs	9,06,819		11,33,900	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(67,95,965)	-	(24,73,078)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables			-	
Other non-current assets			-	
Other Current assets	(48,200)		94,790	
Inventories	-			
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(7,04,359)		(3,72,863)	
Provision (CL)	37,91,885		5,400	
Borrowing (CL)	44,43,582		16,50,001	
Other financial liabilities				
Other current liabilities	(6,66,681)		11,08,973	
Provison (NCL)			-	
Cash generated from operations		20,262		13,223
Net income tax paid		-		-
Net cash flow from operating activities (A)		20,262		13,223
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	(14,661)			
Investments	-			
Non Current Assets	(58,046)		(59,887)	
Net cash (used in) / flow from investing activities (B)		(72,707)		(59,887)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		(52,445)		(46,664)
Cash and cash equivalents at the beginning of the year		1,51,227		1,41,743
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
		-		-
Cash and cash equivalents at the end of the year		98,782		95,079

For and on behalf of the Board of Directors
M/s TRANSGENE BIOTEK LIMITED



Dr.K K Koteswara Rao
Chairman & Managing Director
DIN:02287235
Date :12-11-2022





Limited Review Report

To,
The Board of Directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 Sep 2022 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. Our view of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities

Name of the entity	Relationship
1. Transgene Biotek HK Limited	Subsidiary
2. PerOral Bio Private Limited	Subsidiary



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of two subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 Sep 2022, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S



Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date: 12.11.2022

Unique Document Identification Number (UDIN) for this document is:
22212664BCXBKZ4179



Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 Sep 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRN No. 010114S



Manisha Dubey
Proprietor
M No. 212664
Place: Hyderabad
Date: 12.11.2022

Unique Document Identification Number (UDIN) for this document is:
22212664BCXBKZ4179